A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

IntegriMedical has introduced a needle-free injection system (N-FIS) that eliminates the need for any prick or piercing, ...

SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for TransCon ® CNP (navepegritide) for the treatment of children with achondroplasia, a rare ...

DataM Intelligence | competitive Intelligence Achondroplasia drug market sees rising competition, with weekly and oral treatments targeting ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Eli Lilly and Company today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at ...

Allergy sufferers in Malta might soon breathe a little easier. A local leader in healthcare distribution has just launched ...

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

Luton, Bedfordshire, United Kingdom, June 05, 2025 (GLOBE NEWSWIRE) -- The global pediatric glioma drugs market is poised for substantial growth, with an estimated value of approximately USD 5 billion ...